CCL17 and Alzheimer disease: (64) found in the experiments that GPN279 can effectively improve the skin barrier and physiological indicators of patients with mild to moderate AD (GPN279, a chemical neutralizing agent, was recently found to bind CCL17 with high affinity and effectively neutralize CCL17, thereby activating the CCR4 receptor expressed by Th2 cells).